New Data Bolster Case for Anti-HER2 Combo in Early Breast Ca
SAN ANTONIO — Adding a second anti-HER2 agent to trastuzumab (Herceptin) plus chemotherapy in the adjuvant setting continued to show promise for select women with early HER2-positive breast cancer, a new analysis from the APHINITY trial indicated. At over 6 years of median follow-up, however, a significant overall survival (OS) benefit …
News story posted on 2019-12-15T14:30:00.0000000Z
